- Home
- TEI vs AMRN Comparison
TEI vs AMRN Comparison
Compare TEI & AMRN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | TEI | AMRN |
|---|---|---|
| Founded | 1993 | 1989 |
| Country | United States | Ireland |
| Employees | N/A | N/A |
| Industry | Finance Companies | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 310.3M | 287.9M |
| IPO Year | N/A | 1998 |
Fundamental Metrics
Financial Performance| Metric | TEI | AMRN |
|---|---|---|
| Price | $6.18 | $13.56 |
| Analyst Decision | | Strong Sell |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $12.00 |
| AVG Volume (30 Days) | ★ 137.7K | 52.0K |
| Earning Date | 01-01-0001 | 04-29-2026 |
| Dividend Yield | ★ 10.51% | N/A |
| EPS Growth | N/A | ★ 55.00 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $181,104,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $1.26 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 39.22 |
| 52 Week Low | $5.75 | $12.96 |
| 52 Week High | $7.00 | $20.90 |
Technical Indicators
Market Signals| Indicator | TEI | AMRN |
|---|---|---|
| Relative Strength Index (RSI) | 30.10 | 42.48 |
| Support Level | $6.21 | $13.32 |
| Resistance Level | $6.89 | $14.50 |
| Average True Range (ATR) | 0.10 | 0.37 |
| MACD | -0.03 | -0.02 |
| Stochastic Oscillator | 3.77 | 32.37 |
Price Performance
Historical ComparisonAbout TEI Templeton Emerging Markets Income Fund Inc.
Templeton Emerging Markets Income Fund is a closed-end fund. It seeks high, current income, with a secondary goal of capital appreciation, by investing, under normal market conditions. The company's investment portfolio includes Foreign Government and Agency Securities; Quasi-Sovereign and Corporate Bonds; Common Stocks and Other Equity Interests, and Short-Term Investments, and Money Market Funds.
About AMRN Amarin Corporation plc
Amarin Corp PLC is a pharmaceutical company. The company is focused on the commercialization and development of therapeutics to improve cardiovascular, or CV, health and reduce CV risk. Its commercialized product includes Vascepa. The company focuses on treatments to stop cardiovascular disease causing death, by providing patients, doctors and investors with reliable cardiovascular treatment options. Geographically, the company derives maximum revenue from United States.